Pre-analytical stability of FGF23 with the contemporary immunoassays

Niek F Dirks; Edward R Smith; Natasja M van Schoor; Marc G Vervloet; Mariëtte T Ackermans; Robert de Jonge; Annemieke C Heijboer

doi:10.1016/j.cca.2019.02.032

Pre-analytical stability of FGF23 with the contemporary immunoassays

Clin Chim Acta. 2019 Jun:493:104-106. doi: 10.1016/j.cca.2019.02.032. Epub 2019 Mar 1.

Authors

Niek F Dirks¹, Edward R Smith², Natasja M van Schoor³, Marc G Vervloet⁴, Mariëtte T Ackermans⁵, Robert de Jonge⁶, Annemieke C Heijboer⁷

Affiliations

¹ Amsterdam UMC, Vrije Universiteit Amsterdam, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam, Netherlands.
² The Royal Melbourne Hospital, Department of Nephrology, Melbourne, Australia; University of Melbourne, Department of Medicine, Melbourne, Australia; Monash University, Department of Renal Medicine, Eastern Health Clinical School, Melbourne, Australia.
³ Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam, Netherlands.
⁴ Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, Nephrology, Amsterdam, Netherlands.
⁵ Amsterdam UMC, University of Amsterdam, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam, Netherlands.
⁶ Amsterdam UMC, Vrije Universiteit Amsterdam, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam, Netherlands; Amsterdam UMC, University of Amsterdam, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam, Netherlands.
⁷ Amsterdam UMC, Vrije Universiteit Amsterdam, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam Gastroenterology & Metabolism, Amsterdam, Netherlands; Amsterdam UMC, University of Amsterdam, Endocrine Laboratory, Department of Clinical Chemistry, Amsterdam, Netherlands. Electronic address: a.heijboer@vumc.nl.

PMID: 30826370
DOI: 10.1016/j.cca.2019.02.032

Abstract

Background: Several publications have reported on the pre-analytical stability of fibroblast growth factor 23 (FGF23) and some recommend coating blood collecting tubes with protease inhibitors, in order to prevent degradation. These recommendations are based on observations for a first generation assay for the measurement of intact FGF23. However, if this also applies for the contemporary immunoassays, and at what stage of pre-analysis, is unknown.

Methods: We reviewed data from these previous reports on the issue of FGF23 stability and complemented these findings with data from novel experiments.

Results: We concluded that the contemporary intact FGF23 assays by Immutopics, Kainos, Millipore and DiaSorin do not suffer from immediate loss of FGF23 signal and do not require blood withdrawal in protease inhibitor-coated collecting tubes. Nevertheless, FGF23 concentrations do decline when centrifugation is delayed up to 8 h and prompt centrifugation is therefore advised.

Keywords: FGF23 immunoassays; Pre-analytical stability; Protease inhibitors.

MeSH terms

Fibroblast Growth Factor-23
Fibroblast Growth Factors / analysis*
Humans
Immunoassay*

Substances

FGF23 protein, human
Fibroblast Growth Factors
Fibroblast Growth Factor-23